STN Structure Search
Registry / Caplus

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS 25	DEC 01	CAS REGISTRY updated with new ambiguity codes

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:25:01 ON 01 DEC 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:25:07 ON 01 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7
DICTIONARY FILE UPDATES: 30 NOV 2006 HIGHEST RN 914452-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525439\1_X=0.str

chain nodes :
1 2 3 6 7 8 11 13 17
ring nodes :
18 19 20 21 22 23
chain bonds :
1-2 1-3 1-6 6-7 7-8 7-11 11-13 13-17 17-18
ring bonds :
18-19 18-20 19-20 19-21 20-23 21-22 22-23
exact/norm bonds :
1-2 7-8 11-13 13-17 18-19 18-20 19-20 21-22 22-23
exact bonds :
1-3 1-6 6-7 7-11 17-18 19-21 20-23

G1:O,S,N

Connectivity :
3:2 M minimum RC ring/chain
Match level :
1:CLASS 2:Atom 3:Atom 6:CLASS 7:CLASS 8:CLASS 11:CLASS 13:CLASS 17:CLASS
18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
Generic attributes :
2:
Saturation : Unsaturated
3:
Saturation : Saturated

Element Count :
Node 3: Limited
C,C3-7

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:25:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 286629 TO ITERATE

100.0% PROCESSED 286629 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.05

L2 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10525439\1_X=1.str





chain nodes :
1 2 3 6 7 8 11 12 14 18
ring nodes :
19 20 21 22 23 24
chain bonds :
1-2 1-3 1-6 6-7 7-8 7-11 11-12 12-14 14-18 18-19
ring bonds :
19-20 19-21 20-21 20-22 21-24 22-23 23-24
exact/norm bonds :
1-2 7-8 7-11 11-12 12-14 14-18 19-20 19-21 20-21 22-23 23-24
exact bonds :
1-3 1-6 6-7 18-19 20-22 21-24

G1:O,S,N

Connectivity :
3:2 M minimum RC ring/chain
Match level :
1:CLASS 2:Atom 3:Atom 6:CLASS 7:CLASS 8:CLASS 11:CLASS 12:CLASS 14:CLASS
18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
Generic attributes :
2:
Saturation : Unsaturated
3:
Saturation : Saturated

Element Count :
Node 3: Limited
C,C3-7

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3 full
FULL SEARCH INITIATED 14:25:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 286629 TO ITERATE

100.0% PROCESSED 286629 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.06

L4 0 SEA SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\10525439\3.str





chain nodes :
1 2 3 5 6 7 10 12 14 25
ring nodes :
15 16 17 18 19 20
chain bonds :
1-2 1-3 1-5 5-6 6-7 6-25 10-12 10-25 12-14 14-15
ring bonds :
15-16 15-17 16-17 16-18 17-20 18-19 19-20
exact/norm bonds :
1-2 1-3 6-7 6-25 10-12 10-25 12-14 15-16 15-17 16-17 18-19 19-20
exact bonds :
1-5 5-6 14-15 16-18 17-20

G1:O,S,N

Match level :
1:CLASS 2:Atom 3:Atom 5:CLASS 6:CLASS 7:CLASS 10:CLASS 12:CLASS 14:CLASS
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 25:CLASS
Element Count :
Node 3: Limited
C,C3-7

L5 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10525439\2.str

chain nodes :
1 2 3 5 6 7 10 12 14
ring nodes :
15 16 17 18 19 20
chain bonds :
1-2 1-3 1-5 5-6 6-7 6-10 10-12 12-14 14-15
ring bonds :
15-16 15-17 16-17 16-18 17-20 18-19 19-20
exact/norm bonds :
1-2 1-3 6-7 10-12 12-14 15-16 15-17 16-17 18-19 19-20
exact bonds :
1-5 5-6 6-10 14-15 16-18 17-20

G1:O,S,N

Match level :
1:CLASS 2:Atom 3:Atom 5:CLASS 6:CLASS 7:CLASS 10:CLASS 12:CLASS 14:CLASS
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
Element Count :
Node 3: Limited

C,C3-7

L6 STRUCTURE UPLOADED

=> s l5 full
FULL SEARCH INITIATED 14:37:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 286629 TO ITERATE

100.0% PROCESSED 286629 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.05

L7 0 SEA SSS FUL L5

=> s l6 full
FULL SEARCH INITIATED 14:37:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 293551 TO ITERATE

100.0% PROCESSED 293551 ITERATIONS 267 ANSWERS
SEARCH TIME: 00.00.06

L8 267 SEA SSS FUL L6

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	675.68	675.89

FILE 'CAPLUS' ENTERED AT 14:38:15 ON 01 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9 8 L8

=> d ibib abs hitstr 1-8

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:1174148 CAPLUS
DOCUMENT NUMBER: 145:471412
TITLE: Preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives as muscarinic receptor antagonists for use against respiratory, urinary and gastrointestinal diseases
INVENTOR(S): Salman, Mohammad; Kumar, Naresh; Kaur, Kirandeep; Arora, Shelly; Sarma, Pakala Kumara Savithru; Dharmarajan, Sankaranarayanan; Mehta, Anita; Chugh, Anita
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117754	A1	20061109	WO 2006-IB51368	20060501

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2005-DE1810 A 20050503
IN 2006-DE1681 A 20060328

GI



I

AB The present invention generally relates to azabicyclo[3.1.0]hexane derivs. (shown as I; variables defined below; e.g. N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2-hydroxy-2-phenyl-2-(2-thienyl)acetamide (1)) as muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepn. of disclosed compds., pharmaceutical compns. contg. the disclosed compds., and the methods for treating diseases mediated through muscarinic receptors. For I: R1 is H or alkyl; R2 is straight or branched alkyl alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl or heteroaryl (un)substituted with ≥1 alkyl, hydroxy or halogen. R3 is aryl or heteroaryl (un)substituted with ≥1 alkyl, hydroxy or halogen; W = -(CH2)i; Q = -(CH2)j; X is O or -N(R5)-; R4 is H, straight or branched alkyl, straight or branched alkenyl, aralkyl or heteroarylalkyl wherein the said aralkyl or heteroarylalkyl is further substituted with alkyl, -NH2 or alkoxycarbonylamino; R5 is H or alkyl; Rw is H or Me; and n, i, j = 0-2. Results of radioligand binding assays for M2 and M3 muscarinic receptors are reported for many examples of I. Methods of prepn. are claimed and prepns. and/or characterization data for .apprx.120 examples of I are included. For example, 1 was prepd. from hydroxy(phenyl)(thien-2-yl)acetic acid and 3-benzyl-3-azabicyclo[3.1.0]hexan-6-amine in DMF using hydroxybenzotriazole, N-methylmorpholine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

IT 913981-38-1P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-3-hydroxy-N-methyl-3,3-diphenylpropanamide 913981-41-6P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2,2-bis(3-methylphenyl)acetamide 913982-44-2P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl methoxydiphenylacetate 913982-49-7P, tert-Butyl [6-[[6-[[(cyclohexyl(hydroxy)phenylacetyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]methyl]pyridin-2-yl]carbamate 913982-55-5P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-3-hydroxy-N-methyl-3,3-diphenylpropionamide 913982-66-8P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-hydroxy-2-(2-thienyl)acetamide tartrate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists for use against respiratory, urinary and gastrointestinal diseases)

RN 913981-38-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-41-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-44-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-49-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-55-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-66-8 CAPLUS
CN 2-Thiopheneacetamide, N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-α-cyclopentyl-α-hydroxy-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-65-7
CMF C17 H24 N2 O2 S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 913981-27-8P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-phenyl-2-(2-thienyl)acetamide 913981-29-0P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-phenyl-2-(3-thienyl)acetamide 913981-30-3P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2-phenyl-2-(3-thienyl)acetamide 913981-31-4P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2,2-bis(thien-2-yl)acetamide 913981-32-5P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2-phenyl-2-(2-thienyl)acetamide 913981-33-6P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-hydroxy-N-methyl-2-(2-thienyl)acetamide 913981-34-7P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2-(4-methylphenyl)-2-(2-thienyl)acetamide 913981-35-8P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-(4-methylphenyl)-2-(2-thienyl)acetamide 913981-39-2P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-3-hydroxy-3,3-diphenylpropanamide 913981-40-5P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-(2-hydroxy-5-methylphenyl)-2-phenylacetamide 913981-42-7P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-methoxy-2,2-diphenylacetamide 913981-44-9P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-methoxy-N-methyl-2,2-diphenylacetamide 913981-46-1P, (3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclohexyl(hydroxy)phenylacetate 913981-47-2P, N-[(3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide 913981-48-3P, N-[(3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide 913981-49-4P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cycloheptyl-2-hydroxy-2-phenylacetamide 913981-50-7P,

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclohexyl-2-hydroxy-N-methyl-2-phenylacetamide 913981-51-8P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2,2-diphenylacetamide 913981-53-0P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-methoxy-2-phenylacetamide 913981-59-6P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2-phenyl-2-(pyridin-3-yl)acetamide 913981-61-0P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-phenyl-2-(pyridin-3-yl)acetamide 913981-63-2P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-N-methyl-2,2-diphenyl-2-propoxyacetamide 913981-64-3P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-N-methyl-2,2-diphenylpropanamide 913981-65-4P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(phenyl)(pyridin-2-yl)acetate 913981-67-6P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(phenyl)(thien-2-yl)acetate 913981-69-8P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(4-methylphenyl)(thien-2-yl)acetate 913981-70-1P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxybis(2-thienyl)acetate 913981-71-2P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl 3-hydroxy-3,3-diphenylpropanoate 913981-72-3P, (3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)phenylacetate 913981-73-4P, (3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxydiphenylacetate 913981-76-7P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(4-methylphenyl)phenylacetate 913981-77-8P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(phenyl)(pyridin-3-yl)acetate 913981-79-0P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2,2-bis(3-methylphenyl)acetamide 913981-81-4P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-2-phenyl-2-(2-thienyl)acetamide 913981-82-5P, (3-Azabicyclo[3.1.0]hex-6-yl)methyl hydroxybis(3-methylphenyl)acetate 913981-84-7P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2,2-bis(3-methylphenyl)acetamide 913981-85-8P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-3-hydroxy-3,3-diphenylpropanamide 913981-86-9P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-methoxy-N-methyl-2,2-diphenylacetamide 913981-88-1P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-methoxy-2,2-diphenylacetamide 913981-89-2P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-methoxy-2-(4-methylphenyl)-2-phenylacetamide 913981-90-5P, (3-Azabicyclo[3.1.0]hex-6-yl)methyl 2,2-diphenyl-2-(propoxy)acetate 913981-92-7P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-N-methyl-2,2-diphenyl-2-propoxyacetamide 913981-94-9P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2,2-diphenyl-2-propoxyacetamide 913981-96-1P, (3-Azabicyclo[3.1.0]hex-6-yl)methyl hydroxybis(4-methylphenyl)acetate 913981-97-2P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2,2-bis(4-fluorophenyl)-2-hydroxy-N-methylacetamide 913981-99-4P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2,2-bis(4-methylphenyl)acetamide 913982-01-1P, (2-Methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclohexyl(hydroxy)phenylacetate 913982-04-4P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-N-methyl-2,2-diphenylpropanamide 913982-05-5P, 2-Hydroxy-N-[(3-methyl-3-

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

azabicyclo[3.1.0]hex-6-yl)methyl]-2-phenyl-2-(2-thienyl)acetamide 913982-07-7P, (3-Methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(3-methylphenyl)phenylacetate 913982-09-9P, 2-Hydroxy-N-methyl-2,2-diphenyl-N-[[3-[(2-thienyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-11-3P,

2-Cyclopentyl-2-hydroxy-N-[(3-methyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-phenylacetamide 913982-13-5P, 2-Cyclopentyl-2-hydroxy-2-phenyl-N-[[3-[(2-thienyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-15-7P, 2-Cyclohexyl-2-hydroxy-N-[[3-[(6-methylpyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-phenylacetamide 913982-19-1P, 2-Cycloheptyl-2-hydroxy-2-phenyl-N-[[3-[(pyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-21-5P, 2-Cyclopentyl-2-hydroxy-N-[[3-[(6-methylpyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-phenylacetamide 913982-23-7P, 2-Hydroxy-N-[[3-(3-methylbut-2-en-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2,2-diphenylacetamide 913982-25-9P, 2-Hydroxy-N-[[3-(4-methylpent-3-en-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2,2-diphenylacetamide 913982-27-1P, 2-Cycloheptyl-2-hydroxy-2-phenyl-N-[[3-[(pyridin-3-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-29-3P, 2-Cycloheptyl-2-hydroxy-2-phenyl-N-[[3-[(pyridin-4-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-31-7P, 2-Cyclopentyl-2-hydroxy-2-phenyl-N-[[3-(2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-33-9P, N-[[3-[(1,3-Benzodioxol-5-yl)methyl]-3-

azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide 913982-34-0P, 2-Cyclohexyl-2-hydroxy-2-phenyl-N-[[3-(2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-35-1P, N-[[3-[2-(1,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-cycloheptyl-2-hydroxy-2-phenylacetamide 913982-36-2P, 2-Cycloheptyl-N-[[3-[2-(2,3-dihydrobenzo[b]furan-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-hydroxy-2-phenylacetamide 913982-37-3P, 2-Cyclopentyl-N-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-hydroxy-2-phenylacetamide 913982-38-4P, [3-[(1,3-Benzodioxol-5-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl cyclohexyl(hydroxy)phenylacetate 913982-39-5P, 2-Hydroxy-2,2-diphenyl-N-[(3-(2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]acetamide 913982-40-8P,

N-{[3-[2-(1,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2-cyclopentyl-2-hydroxy-N-methyl-2-phenylacetamide 913982-41-9P,

2-Hydroxy-N-methyl-N-[[3-(4-methylpent-3-en-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2,2-diphenylacetamide 913982-42-0P,

N-[[3-[2-(1,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-hydroxy-N-methyl-2,2-diphenylacetamide 913982-43-1P, N-[[3-[2-(2,3-Dihydrobenzo[b]furan-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-hydroxy-N-methyl-2,2-diphenylacetamide 913982-46-4P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl hydroxy(phenyl)(thien-3-yl)acetate 913982-47-5P, (3-Azabicyclo[3.1.0]hex-6-yl)methyl methoxydiphenylacetate 913982-50-0P, tert-Butyl [6-[[6-[[(hydroxydiphenylacetyl)amino]methyl]-3-azabicyclo[3.1.0]hex-3-

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

yl]methyl]pyridin-2-yl]carbamate 913982-51-1P, tert-Butyl [6-[[6-[[[cyclopentyl(hydroxy)phenylacetyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]methyl]pyridin-2-yl]carbamate 913982-52-2P, N-[[3-[(6-Aminopyridin-2-yl)methyl]-3-

azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide 913982-53-3P, N-[[3-[(6-Aminopyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide 913982-54-4P, N-[[3-[(6-Aminopyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-hydroxy-2,2-diphenylacetamide 913982-56-6P, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-3-hydroxy-N-methyl-3,3-diphenylpropanamide tartrate 913982-60-2P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-hydroxy-2-(2-thienyl)acetamide tartrate 913982-68-0P

N-[[3-[(6-Aminopyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide tartrate 913982-70-4P,

N-[[3-[(6-Aminopyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide tartrate 913982-72-6P, N-[(3-Benzyl-2-methyl-3-azabicyclo[3.1.0]hex-6-yl]methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide tartrate 913982-75-9P, [3-(4-Methylpent-3-en-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl cyclopentyl(hydroxy)phenylacetate tartrate 913982-78-2P, [3-(1-Phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl cyclohexyl(hydroxy)phenylacetate tartrate 913982-82-8P,

N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclobutyl-2-hydroxy-2-phenylacetamide tartrate 913982-85-1P, [3-(3-Methylbut-2-en-1-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl cyclopentyl(hydroxy)phenylacetate tartrate 913982-88-4P, [3-[(1,3-Benzodioxol-5-yl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl cyclopentyl(hydroxy)phenylacetate tartrate 913982-90-8P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclohexyl-2-hydroxy-N-methyl-2-phenylacetamide tartrate 913982-93-1P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-hydroxy-N-methyl-2,2-diphenylacetamide tartrate 913982-97-5P, (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)(thien-2-yl)acetate tartrate 913983-00-3P, N-[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclopentyl-2-hydroxy-N-methyl-2-phenylacetamide tartrate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists for use against respiratory,

urinary and gastrointestinal diseases)

RN 913981-27-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 913981-29-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 913981-30-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 913981-31-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 913981-32-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 913981-33-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 913981-34-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-35-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-39-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-40-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-42-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-46-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-47-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-48-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-50-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-51-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-53-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-59-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-61-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-63-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-64-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-65-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-67-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-69-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-70-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-71-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-72-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-73-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-76-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-77-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 913981-79-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-81-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-82-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-84-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-85-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-86-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-88-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-89-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-90-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-92-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913981-94-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-96-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-97-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913981-99-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913982-01-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-04-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-05-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-07-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 913982-09-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-11-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-13-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-15-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-19-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 913982-21-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-23-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-25-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-27-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-29-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-31-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913982-33-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-34-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-35-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-36-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-37-3 CAPLUS

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN. (Continued)
CN INDEX NAME NOT YET ASSIGNED



RN 913982-38-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-39-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-40-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-41-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-42-0 CAPLUS

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN INDEX NAME NOT YET ASSIGNED



RN 913982-43-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-46-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-47-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-50-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-51-1 CAPLUS

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN INDEX NAME NOT YET ASSIGNED



RN 913982-52-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-53-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-54-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 913982-56-6 CAPLUS
CN Benzenepropanamide, N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-β-hydroxy-N-methyl-β-phenyl-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 913982-55-5
CMF C22 H26 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-60-2 CAPLUS
CN 2-Thiopheneacetamide, α-cyclopentyl-α-hydroxy-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-59-9
CMF C24 H30 N2 O2 S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-72-6 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[2-methyl-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913981-48-3
CMF C28 H36 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913982-68-0 CAPLUS
CN Benzeneacetamide, N-[[3-[(6-amino-2-pyridinyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-53-3
CMF C25 H32 N4 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-70-4 CAPLUS
CN Benzeneacetamide, N-[[3-[(6-amino-2-pyridinyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclohexyl-α-hydroxy-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-52-2
CMF C26 H34 N4 O2

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913982-75-9 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-74-8
CMF C25 H35 N O3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-78-2 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-77-1
CMF C28 H35 N O3

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-82-8 CAPLUS
CN Benzeneacetamide, α-cyclobutyl-α-hydroxy-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-81-7
CMF C25 H30 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-90-8 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-methyl-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913981-50-7
CMF C28 H36 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-93-1 CAPLUS

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 913982-85-1 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-84-0
CMF C24 H33 N O3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-88-4 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-87-3
CMF C27 H31 N O5

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzeneacetamide, α-hydroxy-N-methyl-α-phenyl-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913981-51-8
CMF C28 H30 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 913982-97-5 CAPLUS
CN 2-Thiopheneacetic acid, α-cyclopentyl-α-hydroxy-, [3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-96-4
CMF C24 H29 N O3 S



CM 2

CRN 87-69-4
CMF C4 H6 O6

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 913983-00-3 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-methyl-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 913982-99-7
CMF C27 H34 N2 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 913982-17-9, N-[(3-Azabicyclo[3.1.0]hex-6-yl)methyl]-2-cyclohexyl-2-hydroxy-2-phenylacetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists for use against respiratory, urinary and gastrointestinal diseases)
RN 913982-17-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:605804 CAPLUS
DOCUMENT NUMBER: 145:83209
TITLE: Preparation of azabicyclo[3.1.0]hexanes-acid addition salts as muscarinic receptor antagonists
INVENTOR(S): Salman, Mohammad; Kumar, Naresh; Yadav, Gyan Chand; Sarma, Pakala Kumara Savithru
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064304	A1	20060622	WO 2004-IB4142	20041215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2004-IB4142 20041215

OTHER SOURCE(S): MARPAT 145:83209
GI



AB Title compds. I [R1 = optionally substituted phenyl; R2 = optionally substituted alkyl with halo, optionally substituted Ph with halo, optionally substituted cycloalkyl with halo; X = -NH-, -O-, NMe; A = organic acid selected from acetic acid, succinic acid, maleic acid, etc., inorg. acid selected from hydrochloric acid, hydrobromic acid, phosphoric acid, etc. with the proviso that A can not be tartaric acid when R1 and R2 are Ph and X is -NMe] and pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, prodrugs, polymorphs and metabolites thereof were prepared For example, a mixture of (2R)-N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-(3,3-difluorocyclopentyl)-2-hydroxy-2-phenylacetamide (II) and L-tartaric acid was stirred at room temp. for 4 h to give L-tartaric acid salt of compd. II. In muscarinic receptor binding assays, the Ki values of 34 examples were in the range of from about 0.01 to about 2 nM for rat M3 receptors, from about 0.01 to about about 25 nM for rat M2 receptors. Compds. I are claimed useful for the treatment of urinary incontinence, bronchial asthma, etc.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 893426-84-1P 893426-87-4P 893426-88-5P
893426-89-6P 893426-90-9P 893426-92-1P
893426-94-3P 893426-95-4P 893426-96-5P
893426-97-6P 893426-98-7P 893427-00-4P
893427-01-5P 893427-02-6P 893427-03-7P
893427-04-8P 893427-05-9P 893427-07-1P
893427-09-3P 893427-10-6P 893427-11-7P
893427-13-9P 893427-16-2P 893427-19-5P
893427-21-9P 893427-23-1P 893427-32-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclo[3.1.0]hexanes-acid addition salts as muscarinic receptor antagonists for treatment of urinary incontinence, bronchial asthma, etc.)
RN 893426-84-1 CAPLUS
CN Benzeneacetic acid, α-hydroxy-α-phenyl-, (1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 893426-87-4 CAPLUS
CN Butanedioic acid, compd. with rel-N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-N-methyl-α-phenylbenzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-86-3
CMF C21 H24 N2 O2

Relative stereochemistry.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-15-6
CMF C4 H6 O4

RN 893426-88-5 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-N-methyl-α-phenyl-, rel-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-86-3
CMF C21 H24 N2 O2

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 893426-92-1 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-91-0
CMF C19 H24 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 893426-94-3 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxy-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-91-0
CMF C19 H24 F2 N2 O2

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 893426-89-6 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-N-methyl-α-phenyl-, rel-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-86-3
CMF C21 H24 N2 O2

Relative stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 893426-90-9 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-N-methyl-α-phenyl-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-86-3
CMF C21 H24 N2 O2

Relative stereochemistry.



L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 893426-95-4 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-91-0
CMF C19 H24 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 893426-96-5 CAPLUS
CN Propanedioic acid, compd. with N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxybenzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-91-0
CMF C19 H24 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 141-82-2
CMF C3 H4 O4

RN 893426-97-6 CAPLUS
CN Hexanedioic acid, compd. with N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxybenzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-91-0
CMF C19 H24 F2 N2 O2

Absolute stereochemistry.



CM 2

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 893427-01-5 CAPLUS
CN 1,3-Cyclopentanedicarboxylic acid, 1,2,2-trimethyl-, (1R,3S)-rel-, compd. with rel-(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl α-hydroxy-α-phenylbenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-99-8
CMF C20 H21 N O3

Relative stereochemistry.



CM 2

CRN 5394-83-2
CMF C10 H16 O4

Relative stereochemistry.



RN 893427-02-6 CAPLUS
CN 3-Pyridinecarboxylic acid, compd. with rel-(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl α-hydroxy-α-phenylbenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-99-8
CMF C20 H21 N O3

Relative stereochemistry.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 124-04-9
CMF C6 H10 O4

RN 893426-98-7 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-N-methyl-α-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 893427-00-4 CAPLUS
CN Ascorbic acid, compd. with rel-(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl α-hydroxy-α-phenylbenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-99-8
CMF C20 H21 N O3

Relative stereochemistry.



CM 2

CRN 62624-30-0
CMF C6 H8 O6

Relative stereochemistry.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 59-67-6
CMF C6 H5 N O2



RN 893427-03-7 CAPLUS
CN Butanoic acid, compd. with rel-(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl α-hydroxy-α-phenylbenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893426-99-8
CMF C20 H21 N O3

Relative stereochemistry.



CM 2

CRN 107-92-6
CMF C4 H8 O2



RN 893427-04-8 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with rel-(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl α-hydroxy-α-phenylbenzeneacetate (1:1) (9CI) (CA

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)

CM 1

CRN 893426-99-8
CMF C20 H21 N O3

Relative stereochemistry.



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 893427-05-9 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 893427-07-1 CAPLUS
CN D-Glucuronic acid, compd. with rel-N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenylbenzeneacetamide (1:1) (9CI) (CA INDEX NAME)

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

CM 1

CRN 893427-06-0
CMF C20 H22 N2 O2

Relative stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P

RN 893427-11-7 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclohexyl-α-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 893427-13-9 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclohexyl-α-hydroxy-, rel-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1

CRN 893427-06-0
CMF C20 H22 N2 O2

Relative stereochemistry.



CM 2

CRN 6556-12-3
CMF C6 H10 O7

Absolute stereochemistry.



RN 893427-09-3 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HBr

RN 893427-10-6 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenyl-, rel-, phosphate (1:1) (salt) (9CI) (CA INDEX

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 893427-12-8
CMF C20 H28 N2 O2

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 893427-16-2 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclohexyl-α-hydroxy-, rel-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893427-12-8
CMF C20 H28 N2 O2

Relative stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 893427-19-5 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-4-fluoro-α-hydroxy-α-phenyl-, rel-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893427-18-4
CMF C20 H21 F N2 O2

Relative stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 893427-21-9 CAPLUS
CN Butanedioic acid, compd. with rel-N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-4-fluoro-α-hydroxy-α-phenylbenzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 893427-18-4
CMF C20 H21 F N2 O2

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 893427-32-2 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-4-fluoro-α-hydroxy-α-phenyl-, rel-, monoperchlorate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893427-18-4
CMF C20 H21 F N2 O2

Relative stereochemistry.



CM 2

CRN 7601-90-3
CMF Cl H O4

IT 893426-91-0 893426-99-8 893427-06-0
893427-12-8 893427-18-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azabicyclo[3.1.0]hexanes-acid addition salts as muscarinic
receptor antagonists for treatment of urinary incontinence, bronchial asthma, etc.)
RN 893426-91-0 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-(3,3-difluorocyclopentyl)-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4

RN 893427-23-1 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-4-fluoro-α-hydroxy-α-phenyl-, rel-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 893427-18-4
CMF C20 H21 F N2 O2

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 893426-99-8 CAPLUS
CN Benzeneacetic acid, α-hydroxy-α-phenyl-, (1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 893427-06-0 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 893427-12-8 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 893427-18-4 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ylmethyl]-4-fluoro-α-hydroxy-α-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:318950 CAPLUS
DOCUMENT NUMBER: 144:369923
TITLE: 3-Azabicyclo[3.1.0]hexane derivatives as muscarinic receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of prophylaxis of of respiratory, urinary, or gastrointestinal diseases
INVENTOR(S): Mehta, Anita; Ahlman, Mohammad; Sarma, Pakala Kumara Savithru Aseem; Shelley; Chugh, Anita; Gupta, Suman
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035282	A2	20060406	WO 2005-IB2838	20050926
WO 2006035282	A3	20060518		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE1849 A 20040927

OTHER SOURCE(S): MARPAT 144:369923
GI

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB This invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compds., pharmaceutical compns. containing the disclosed compds., and the methods for treating diseases mediated through muscarinic receptors. Compds. of formula I wherein R1 is H, C1-6 alkyl, C2-7 alkenyl, C2-7 alkynyl, cycloalkyl, (un)substituted amino, or OH and derivs.; R2 is carboxy, SO2R6, CO2R7, NH2 and derivs., or CONH2 and derivs., etc.; R3 is alkyl, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, aralkyl, or heterocyclyl(alkyl); R4 and R5 are independently H, C1-6 alkyl, C2-7 alkenyl, or C2-7 alkynyl; X is O, NH and derivs., C1-6 alkyl, C2-7 alkenyl, C2-7 alkynyl, aralkyl, or aryl; Ar is (hetero)aryl or heterocyclyl; and their stereoisomers, polymorphs, pharmaceutically acceptable salts, and solvates thereof and methods for preparation are claimed.
Example compound II was prepared by sulfonylation of N-(1α,5α,6α)-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-2-cyclopentyl-2-hydroxy-2-Ph acetamide with p-nitrophenylsulfonyl chloride. All the invention compds. were evaluated for their binding affinity towards muscarinic receptors. From the assay, it was determined that most of the invention compds. exhibited K_i values for M2 and M3 muscarinic receptors in the range of about 1000 nM to about 7.8 nM and 1000 nM to about 0.5 nM, resp.

IT 882164-21-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of azabicyclohexane derivs. as muscarinic receptor antagonists useful for treatment of prophylaxis of of respiratory, urinary, or gastrointestinal diseases)

RN 882164-21-8 CAPLUS

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzeneacetamide, N-[[(1α,5α,6β)-3-chloro-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 882164-17-2P 882164-18-3P 882164-19-4P
882164-20-7P 882164-22-9P 882164-23-0P
882164-24-1P 882164-25-2P 882164-26-3P
882164-27-4P 882164-28-5P 882164-29-6P
882164-30-9P 882164-31-0P 882164-32-1P
882164-33-2P 882164-34-3P 882164-35-4P
882164-36-5P 882164-37-6P 882164-38-7P
882164-39-8P 882164-40-1P 882164-41-2P
882164-42-3P 882164-43-4P 882164-44-5P
882164-45-6P 882164-46-7P 882164-47-8P
882164-48-9P 882164-49-0P 882164-50-3P
882164-51-4P 882164-52-5P 882164-53-6P
882164-54-7P 882164-55-8P 882164-56-9P
882164-57-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azabicyclohexane derivs. as muscarinic receptor antagonists useful for treatment of prophylaxis of of respiratory, urinary, or gastrointestinal diseases)

RN 882164-17-2 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[(4-nitrophenyl)sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-18-3 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-[(3,5-difluorophenyl)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-19-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-(4-methoxybenzoyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-20-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, (4-nitrophenyl)methyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-22-9 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-chloro-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



● HCl

RN 882164-23-0 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-methanamine, 3-cyano-N-(cyclopentylhydroxyphenylacetyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-24-1 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-25-2 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-(phenylmethyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



RN 882164-26-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylmethoxyphenylacetyl)amino]methyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-27-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-(phenylsulfonyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-28-5 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-(3,5-dinitrobenzoyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-29-6 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[(phenylmethoxy)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-30-9 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-benzoyl-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-31-0 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[(3-nitrophenyl)sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-32-1 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-(1,3-benzodioxol-5-ylacetyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-33-2 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[[4-(trifluoromethyl)phenyl]sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-34-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-[4-(trifluoromethyl)phenyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-35-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-36-5 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-(2-fluorobenzoyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-37-6 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[4-(trimethoxymethyl)benzoyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-38-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-(4-fluorophenyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-39-8 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-(phenylacetyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-40-1 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, 2-methylpropyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-41-2 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, 4-nitrophenyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-42-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, phenylmethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-43-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-[(4-fluorophenyl)sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-44-5 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-45-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-2-propenyl-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-46-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-(2,4-dimethoxyphenyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-50-3 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-chloro-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-51-4 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-chloro-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy-α-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-52-5 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, 9H-fluoren-9-ylmethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-47-8 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-(3,5-dimethylbenzoyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-48-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-[4-(phenylmethoxy)phenyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-49-0 CAPLUS

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-53-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-, butyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-54-7 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-(methylsulfonyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-55-8 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[[(cyclopentylhydroxyphenylacetyl)amino]methyl]-N-(2,4-difluorophenyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 882164-56-9 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6β)-3-[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882164-57-0 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6β)-3-[(dimethylamino)sulfonyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 882168-33-4P 882168-34-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azabicyclohexane derivs. as muscarinic receptor antagonists useful for treatment of prophylaxis of of respiratory, urinary, or gastrointestinal diseases)

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 882168-33-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6β)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 882168-34-5 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6β)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:295302 CAPLUS
DOCUMENT NUMBER: 144:350723
TITLE: Preparation of phenyl-substituted amine diols and related compounds as muscarinic receptor antagonists for treating diseases such as those of the respiratory, urinary and gastrointestinal systems
INVENTOR(S): Sultana, Mohammad; Sarma, Pakala Kumara Savithru; Dharmarajan, Sankaranarayanan; Chugh, Anita; Gupta, Suman
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032994	A2	20060330	WO 2005-IB2823	20050923
WO 2006032994	A3	20060504		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-613001P P 20040924

OTHER SOURCE(S): CASREACT 144:350723; MARPAT 144:350723

AB This present invention generally relates to muscarinic receptor antagonists (PhC(X)(OH)C(:G)CH2N(R1)(R2) (I) or PhC(X)(OH)C(G)CH2N(R1)(R2) (II); variables defined below; e.g. 1-cyclopentyl-3-([1,4]diazepan-1-yl)-1-hydroxy-1-phenylpropan-2-one), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compds., pharmaceutical compns. containing the disclosed compds., and the methods for treating diseases mediated through muscarinic receptors. For I and II: X = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, or heteroarylalkyl; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, -(CH2)0-2-heterocyclylalkyl, or -(CH2)0-2-heteroarylalkyl; R2 = -(CH2)0-2-heteroaryl, -(CH2)0-2-heterocyclyl, or -(CH2)0-2-aryl, or R1 and R2 may together combine to form a (un)saturated monocyclic or bicyclic ring system containing 0-4 heteroatoms (O, N or S) wherein the ring can be (un)substituted with ≥1 of alkyl,

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

alkenyl, alkynyl, cycloalkyl, alkaryl, alkoxy, aryloxy, et al.; G = -OR [R = H or unsubstituted lower (C1-C6) alkyl], -NOR, -NHYR' (R' is H, alkyl or aryl and Y is -C(O), -SO or -SO2), or O (provided that R1 and R2 together does not form a pyrrolidine, 4-hydroxypiperidine, 4-pyrrolidinylpiperidine, piperazine or azabicyclo[3.1.0]hexane ring). Methods of prepn. are claimed and prepns. and/or characterization data for .apprx.80 examples of I are included. For example, 1-cyclopentyl-1-hydroxy-1-phenyl-3-(piperidin-1-yl)propan-2-one was prepd. (86 %) from piperidine, Et3N and 3-bromo-1-cyclopentyl-1-hydroxy-1-phenyl-2-propanone (prepn. described) in CH2Cl2. Ki values for I tested in a radioligand binding assay range from .apprx.5 nM to .apprx.10 μM for M2 receptors, and from .apprx.0.5 nM to .apprx.10 μM for M3 receptors. Selectivity for bladder pressure inhibition vs. salivation was detd. for compd. 3 examples of I and was .apprx.2, similar to that detd. for tolterodine.

IT 881098-71-1P, 3-[[(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl](methyl)amino]-1-cyclopentyl-1-hydroxy-1-phenylpropan-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Ph-substituted amine diols and related compds. as muscarinic receptor antagonists for treating diseases such as those of respiratory, urinary and gastrointestinal systems)
RN 881098-71-1 CAPLUS
CN 2-Propanone, 1-cyclopentyl-1-hydroxy-3-[methyl[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]amino]-1-phenyl- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:30422 CAPLUS
DOCUMENT NUMBER: 144:114451
TITLE: Solid oral dosage forms of azabicyclo derivatives
INVENTOR(S): Rao, Korlapati Venkateswara; Karatgi, Pradeep Jai Rao; Murthy, Vyanampudi Sri Rama
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006003587	A2	20060112	WO 2005-IB52104	20050624
WO 2006003587	A3	20060914		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE1234 A 20040701

AB The present invention relates to solid dosage forms for oral administration of an azabicyclo derivative or its pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs and metabolites; and processes for the preparation of such solid dosage forms. The solid dosage forms can be characterized as having excellent content uniformity. A capsule contained (2R)-(1-alpha, 5-alpha, 6-alpha)-N-[3-azabicyclohexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-Ph acetamide hydrochloride 0.10, lactose monohydrate 54.40, microcryst. cellulose 30.00, croscarmellose sodium 3.00, pre-gelatinized starch 10.00, purified water q.s., magnesium stearate 1.00, talc 1.00, and colloidal silicon dioxide 0.50 mg.

IT 872994-89-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid oral dosage forms of azabicyclo derivs.)

RN 872994-89-3 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclopentyl-α-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



● HCl

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1075634 CAPLUS
DOCUMENT NUMBER: 143:373316
TITLE: Combination therapy using adrenergic receptor antagonist in combination with muscarinic receptor antagonists and testosterone 5-reductase inhibitors for lower urinary tract symptoms
INVENTOR(S): Chugh, Anita; Tiwari, Atul
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092341	A1	20051006	WO 2004-IB842	20040322

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005092342	A1	20051006	WO 2004-IB866	20040323

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2004-IB842 A 20040322

AB This invention relates to combination therapy for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with or without BPH. The combination therapy comprises of 1α adrenergic receptor (AR) subtype selective antagonist in combination with muscarinic receptor antagonist and optionally included Testosterone 5-reductase inhibitor for relief of LUTS in a subject with or without BPH.

IT 646036-03-5 646523-27-5 866097-19-0 866186-71-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy using adrenergic receptor antagonist in combination with muscarinic receptor antagonists and testosterone 5-reductase inhibitors for lower urinary tract symptoms)

RN 646036-03-5 CAPLUS
CN Benzeneacetamide, N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-α-

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
cyclopentyl-α-hydroxy-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 646523-27-5 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 866097-19-0 CAPLUS
CN Benzeneacetamide, N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-α-cyclopentyl-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866186-71-2 CAPLUS
CN Benzeneacetamide, N-[(1R,5S)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclopentyl-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:182839 CAPLUS
DOCUMENT NUMBER: 140:235609
TITLE: Fluoro- and sulfonylamino-containing 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives as muscarinic receptor antagonists
INVENTOR(S): Mehta, Anita; Gupta, Jang Bahadur
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018422	A1	20040304	WO 2002-IB3433	20020823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002326072	A1	20040311	AU 2002-326072	20020823
EP 1534675	A1	20050601	EP 2002-760461	20020823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1688544	A	20051026	CN 2002-829770	20020823
JP 2006501236	T2	20060112	JP 2004-530408	20020823
US 2006004083	A1	20060105	US 2005-525439	20050801

PRIORITY APPLN. INFO.: WO 2002-IB3433 A 20020823

OTHER SOURCE(S): CASREACT 140:235609; MARPAT 140:235609
GI

Instant App

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. of formula I [wherein: Ar = (un)substituted (heterolaryl; R1 = H, OH, CH2OH, NH2, alkoxy, carbamoyl, or halogen; R2 = C3-C7 cycloalkyl ring with 1-4 hydrogens substituted by fluorine atoms, or sulfonamide derivs.; R3 = C1-C15 (un)saturated (un)substituted hydrocarbon group; R4 and R5 are selected from H, Me, CO2H, C(O)NH2, NH2, CH2NH2; W = (CH2)0-1; X = O, S, N, bond; Y = CH(R')CO (R' = H or Me) or (CH2)0-4; Z = O, S, NR'' (R'' = H or alkyl); Q = (CH2)1-4, CHR''' (R''' = H, OH, alkyl, alkenyl, alkoxy), or

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CH2CHR'''' (R'''' = H, OH, alkyl, alkoxy)] useful as muscarinic receptor antagonists. Compds. I are useful for the treatment of various muscarinic receptor-mediated respiratory, urinary, and gastrointestinal system diseases; the affinity of test compds. for M2 and M3 muscarinic receptor subtypes was tested. For instance, compd. II [example 2; pKi = 6.9/8.4 for the M2 and M3 receptor subtypes resp.] was prepd. via amidation of phenylacetic acid deriv. III by azabicyclo[3.1.0]hexane deriv. IV (no yield data).

IT 666835-75-2P 666835-76-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fluoro- and sulfonylamino-containing 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists)

RN 666835-75-2 CAPLUS
CN Benzeneacetamide, α-(3-azidocyclopentyl)-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666835-76-3 CAPLUS
CN Benzeneacetamide, α-(3-aminocyclopentyl)-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 666835-57-0P 666835-60-5P 666835-65-0P
666835-72-9P 666835-77-4P 666835-78-5P
666835-79-6P 666835-80-9P 666835-81-0P
667427-00-1P 667427-01-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluoro- and sulfonylamino-containing 3,6-disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists)

RN 666835-57-0 CAPLUS
CN Benzeneacetamide, α-[(1R)-3,3-difluorocyclopentyl]-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



548/515
514/412

RN 666835-60-5 CAPLUS
CN Benzeneacetamide, α-(3-fluorocyclopentyl)-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666835-65-0 CAPLUS
CN Benzeneacetamide, α-(3,3-difluorocyclopentyl)-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 666835-72-9 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-[(1α,5α,6α)-3-[(phenylacetyl)amino]cyclopentyl]-N-[[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 666835-77-4 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-[3-[[(4-nitrophenyl)sulfonyl]amino]cyclopentyl]-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666835-78-5 CAPLUS
CN Benzeneacetamide, α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-[3-[(phenylsulfonyl)amino]cyclopentyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666835-79-6 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-[3-[[(phenylmethoxy)acetyl]amino]cyclopentyl]-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 667427-01-2 CAPLUS
CN Benzeneacetamide, α-(3-fluorocyclopentyl)-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 666835-80-9 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-[3-[[(4-methoxyphenyl)sulfonyl]amino]cyclopentyl]-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666835-81-0 CAPLUS
CN Benzeneacetamide, α-[3-[[(4-bromophenyl)sulfonyl]amino]cyclopentyl]-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667427-00-1 CAPLUS
CN Benzeneacetamide, α-[(1S)-3,3-difluorocyclopentyl]-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:41201 CAPLUS
DOCUMENT NUMBER: 140:111279
TITLE: Preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives useful as muscarinic receptor antagonists
INVENTOR(S): Mehta, Anita; Silamkoti, Arundutt V.; Gupta, Jang Bahadur
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004629	A2	20040115	WO 2002-IB2663	20020708
WO 2004004629	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492121	AA	20040115	CA 2002-2492121	20020708
AU 2002345266	A1	20040123	AU 2002-345266	20020708
BR 2002015801	A	20050510	BR 2002-15801	20020708
EP 1546099	A2	20050629	EP 2002-743489	20020708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1668585	A	20050914	CN 2002-829552	20020708
JP 2006502985	T2	20060126	JP 2004-519029	20020708
NZ 537584	A	20060728	NZ 2002-537584	20020708
CA 2491998	AA	20040115	CA 2003-2491998	20030411
WO 2004005252	A1	20040115	WO 2003-IB1367	20030411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226579	A1	20040123	AU 2003-226579	20030411
BR 2003012572	A	20050510	BR 2003-12572	20030411
EP 1551803	A1	20050713	EP 2003-762827	20030411
EP 1551803	B1	20061011		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681784	A	20051012	CN 2003-821130	20030411
JP 2005535655	T2	20051124	JP 2004-519035	20030411
NZ 537585	A	20060728	NZ 2003-537585	20030411

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AU 2004228452	A1	20041021	AU 2004-228452		20040106
CA 2522071	AA	20041021	CA 2004-2522071		20040106
WO 2004089900	A1	20041021	WO 2004-IB8		20040106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1626957	A1	20060222	EP 2004-700287		20040106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004009302	A	20060411	BR 2004-9302		20040106
CN 1795176	A	20060628	CN 2004-80014471		20040106
JP 2006522787	T2	20061005	JP 2006-506251		20040106
AU 2004228760	A1	20041021	AU 2004-228760		20040107
CA 2521989	AA	20041021	CA 2004-2521989		20040107
WO 2004089364	A1	20041021	WO 2004-IB12		20040107

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1620087	A1	20060201	EP 2004-700488		20040107

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004009308	A	20060502	BR 2004-9308		20040107
CN 1794985	A	20060628	CN 2004-80014502		20040107
JP 2006522788	T2	20061005	JP 2006-506252		20040107
ZA 2005000952	A	20051012	ZA 2005-952		20050202
US 2006111425	A1	20060525	US 2006-520572		20060119
PRIORITY APPLN. INFO.:			WO 2002-IB2663	A	20020708
			WO 2003-IB1367	W	20030411
			WO 2003-IB301367	A	20030411
			WO 2004-IB8	W	20040106
			WO 2004-IB12	W	20040107

OTHER SOURCE(S): MARPAT 140:111279

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

GI



I

AB This invention generally relates to the derivs. of novel 3,6 disubstituted azabicyclo[3.1.0] hexanes. The title compds. [I; Ar = each (un)substituted aryl or heteroaryl having 1-2 hetero atoms selected from the group consisting of O, S and N atoms; R1 = H, HO, hydroxymethyl, amino, alkoxy, carbamoyl or halogen (e.g. F, Cl, Br, iodo); R2 = alkyl, C3-7 cycloalkyl, C3-7 cycloalkenyl, each (un)substituted aryl or heteroaryl having 1 to 2 hetero atoms selected from a group consisting of O, S and N atoms; W = (CH2)p (where p = 0, 1); X = O, S, N, no atom; Y = CHR5CO (wherein R5 = H, Me) or (CH2)q (wherein q = 0-4); Z = O, S, NR10 (wherein R10 = H, C1-6 alkyl); Q = (CH2)n (wherein n = 0-4), or CHR5 (wherein R5 = H, OH, C1-6 alkyl, alkenyl alkoxy) or CH2CHR9 (wherein R9 = H, OH, C1-4 alkyl, C1-C4 alkoxy); R6, R7 = CO2H, H, Me, CONH2, NH2, CH2NH2; R4 = (un)substituted C1-15 saturated or unsatd. aliphatic hydrocarbon groups], pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs, or metabolites thereof are prepared These compds., e.g. (1α,5α,6α)-N-[[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-yl]methyl]-2-hydroxy-2,2-diphenylacetamide, (1α,5α,6α)-N-[[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-yl]methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide, (1α,5α,6α)-N-[[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-yl]methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide, (1α,5α,6α)-[[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-yl]methyl] 2-hydroxy-2,2-diphenylacetate, and are muscarinic receptor antagonists which are useful, inter-alia for the treatment or prophylaxis of various diseases or disorders of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. In particular, the diseases or disorders are urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, and diabetes or gastrointestinal hyperkinesis.

IT 646035-99-6P 646036-01-3P 646036-03-5P 893427-06-0P 893427-12-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists for treatment or prophylaxis of muscarinic receptor-mediated diseases or disorders)

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 646035-99-6 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, (1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646036-01-3 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, (1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646036-03-5 CAPLUS
CN Benzeneacetamide, N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-α-cyclopentyl-α-hydroxy-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 893427-06-0 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-hydroxy-α-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 893427-12-8 CAPLUS
CN Benzeneacetamide, N-[(1α,5α,6α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 646035-38-3P 646035-39-4P 646035-40-7P 646035-41-8P 646035-42-9P 646035-43-0P 646035-44-1P 646035-45-2P 646035-46-3P 646035-47-4P 646035-48-5P 646035-49-6P 646035-50-9P 646035-51-0P 646035-52-1P 646035-53-2P 646035-54-3P 646035-55-4P 646035-56-5P 646035-57-6P 646035-58-7P 646035-59-8P 646035-60-1P 646035-61-2P 646035-62-3P 646035-63-4P 646035-64-5P 646035-65-6P 646035-66-7P 646035-67-8P 646035-68-9P 646035-69-0P 646035-70-3P 646035-71-4P 646035-73-6P 646035-75-8P 646035-77-0P 646035-78-1P 646035-80-5P 646035-81-6P 646035-82-7P 646035-83-8P 646035-84-9P 646035-85-0P 646035-86-1P 646035-87-2P 646035-88-3P 646035-89-4P 646035-90-7P 646035-91-8P 646035-92-9P 646035-93-0P 646035-94-1P 646035-95-2P 646523-26-4P 646523-27-5P 646523-28-6P 646523-29-7P 646523-30-0P 646523-31-1P 646523-32-2P 646523-33-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted azabicyclo[3.1.0]hexane derivs. as muscarinic receptor antagonists for treatment or prophylaxis of muscarinic receptor-mediated diseases or disorders)

RN 646035-38-3 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-phenyl-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 646035-39-4 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-40-7 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-41-8 CAPLUS
CN Benzeneacetic acid, α-hydroxy-α-phenyl-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-42-9 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-43-0 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-44-1 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-45-2 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-46-3 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-N-[[(1α,5α,6α)-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-47-4 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-[[(1α,5α,6α)-3-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-48-5 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-49-6 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-50-9 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6α)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-51-0 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6α)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-52-1 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-53-2 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-54-3 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-55-4 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-56-5 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-57-6 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-58-7 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-59-8 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-60-1 CAPLUS
CN Benzeneacetamide, α-hydroxy-N-[[(1α,5α,6α)-3-(1-methyl-2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-61-2 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(1-methyl-2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-62-3 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(1-methyl-2-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-63-4 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-64-5 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-65-6 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-40-7
CMF C26 H32 N2 O2

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-68-9 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-69-0 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-70-3 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-48-5
CMF C28 H33 N O5

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-66-7 CAPLUS
CN Benzeneacetamide, α-cyclobutyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-67-8 CAPLUS
CN Benzeneacetamide, α-cyclopropyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-71-4 CAPLUS
CN Benzeneacetic acid, α-hydroxy-α-phenyl-, [(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-41-8
CMF C27 H27 N O3

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-73-6 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-42-9
CMF C27 H33 N O3

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-75-8 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-43-0

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C26 H31 N O3

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-77-0 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(3-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-78-1 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(4-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-80-5 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(2-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-81-6 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(4-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-82-7 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-phenyl-N-[[(1α,5α,6α)-3-(3-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 646035-83-8 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-phenyl-N-[[(1α,5α,6α)-3-(4-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-84-9 CAPLUS
CN Benzeneacetamide, α-hydroxy-α-phenyl-N-[[(1α,5α,6α)-3-(2-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-85-0 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(2-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-86-1 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(3-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-87-2 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-88-3 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6α)-3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclopentyl-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646035-89-4 CAPLUS
CN Benzeneacetamide, N-[[(1α,5α,6α)-3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-α-cyclohexyl-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646035-90-7 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1R,5S)-3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-54-3
CMF C26 H37 N O3

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-91-8 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1R,5S)-3-[2-(1,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)

CM 1

CRN 646035-49-6
CMF C29 H35 N O5

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-92-9 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1R,5S)-3-(1-phenylethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-56-5
CMF C27 H33 N O3

Absolute stereochemistry.



L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646035-93-0 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 646035-94-1 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with α-cyclopentyl-α-hydroxy-N-[[(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]benzeneacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-40-7
CMF C26 H32 N2 O2

Absolute stereochemistry.



CM 2

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 646035-95-2 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1R,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646035-40-7
CMF C26 H32 N2 O2

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 646523-26-4 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646523-27-5 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 646523-28-6 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 646523-29-7 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 646523-30-0 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 646523-31-1 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, [(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 646523-32-2 CAPLUS
CN Benzeneacetamide, α-cyclohexyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646523-26-4
CMF C27 H34 N2 O2

Absolute stereochemistry. Rotation (+).

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 646523-33-3 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-α-hydroxy-N-[[(1α,5α,6α)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 646523-27-5
CMF C26 H32 N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)